U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C8H18NO2.I
Molecular Weight 287.1385
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of METHACHOLINE IODIDE

SMILES

[I-].CC(C[N+](C)(C)C)OC(C)=O

InChI

InChIKey=LCQWLOBDIMPRBS-UHFFFAOYSA-M
InChI=1S/C8H18NO2.HI/c1-7(11-8(2)10)6-9(3,4)5;/h7H,6H2,1-5H3;1H/q+1;/p-1

HIDE SMILES / InChI

Description
Curator's Comment: description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/019193s013lbl.pdf | https://www.ncbi.nlm.nih.gov/pubmed/9622546

Methacholine (trade name Provocholine) is a synthetic choline ester that acts as a muscarinic receptor agonist. Methacholine is primarily used to diagnose bronchial hyperreactivity, which is the hallmark of asthma and also occurs in chronic obstructive pulmonary disease. This is accomplished through the bronchial challenge test, or methacholine challenge, in which a subject inhales aerosolized methacholine, leading to bronchoconstriction.

Approval Year

Targets

Targets

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Diagnostic
PROVOCHOLINE

Approved Use

Provocholine® (methacholine chloride powder for inhalation) is indicated for the diagnosis of bronchial airway hyperreactivity in subjects who do not have clinically apparent asthma.

Launch Date

1986
Doses

Doses

DosePopulationAdverse events​
16 mg/mL 5 times / day multiple, respiratory (max)
Recommended
Dose: 16 mg/mL, 5 times / day
Route: respiratory
Route: multiple
Dose: 16 mg/mL, 5 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Bronchial airway hyperreactivity
Sources: Page: p.1
Disc. AE: Bronchoconstriction...
AEs leading to
discontinuation/dose reduction:
Bronchoconstriction (severe)
Sources: Page: p.1
AEs

AEs

AESignificanceDosePopulation
Bronchoconstriction severe
Disc. AE
16 mg/mL 5 times / day multiple, respiratory (max)
Recommended
Dose: 16 mg/mL, 5 times / day
Route: respiratory
Route: multiple
Dose: 16 mg/mL, 5 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Bronchial airway hyperreactivity
Sources: Page: p.1
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer




Drug as perpetrator​Drug as victim
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Conditioned medium from hypoxic cytotrophoblasts alters arterial function.
2001 Apr
Mild exacerbations and eosinophilic inflammation in patients with stable, well-controlled asthma after 1 year of follow-up.
2001 Apr
Comparisons of peak diurnal expiratory flow variation, postbronchodilator FEV(1) responses, and methacholine inhalation challenges in the evaluation of suspected asthma.
2001 Apr
Chromosome 14 linkage analysis and mutation study of 2 serpin genes in allergic asthmatic families.
2001 Apr
Three years of specific immunotherapy with house-dust-mite extracts in patients with rhinitis and asthma: significant improvement of allergen-specific parameters and of nonspecific bronchial hyperreactivity.
2001 Apr
Gibbs sampling-based segregation analysis of asthma-associated quantitative traits in a population-based sample of nuclear families.
2001 Apr
IL-10 gene knockout attenuates allergen-induced airway hyperresponsiveness in C57BL/6 mice.
2001 Feb
Inhibition of phosphodiesterase 4 attenuates airway hyperresponsiveness and airway inflammation in a model of secondary allergen challenge.
2001 Jan
Acute anti-inflammatory effects of inhaled budesonide in asthma: a randomized controlled trial.
2001 Jan
Abnormal responses to endothelial agonists in Raynaud's phenomenon and scleroderma.
2001 Jan
Relaxant effect of Pimpinella anisum on isolated guinea pig tracheal chains and its possible mechanism(s).
2001 Jan
Secretion and gene expression of secretory leukocyte protease inhibitor by human airway submucosal glands.
2001 Jan
Methacholine responsiveness in infants assessed with low frequency forced oscillation and forced expiration techniques.
2001 Jan
Enhancement of goblet cell hyperplasia and airway hyperresponsiveness by salbutamol in a rat model of atopic asthma.
2001 Jan
[Asthma related to inhalation of Plantago ovata].
2001 Jan 13
Developmental expression of neurokinin A and functional neurokinin-2 receptors in lung.
2001 Jun
SCF-induced airway hyperreactivity is dependent on leukotriene production.
2001 Jun
Measurements of resistance by the interrupter technique and of transcutaneous partial pressure of oxygen in young children during methacholine challenge.
2001 Mar
Effect of salmeterol on allergen-induced airway inflammation in mild allergic asthma.
2001 Mar
Assessment of oxidant stress in allergic asthma by measurement of the major urinary metabolite of F2-isoprostane, 15-F2t-IsoP (8-iso-PGF2alpha).
2001 Mar
The transcription factor early growth-response factor 1 modulates tumor necrosis factor-alpha, immunoglobulin E, and airway responsiveness in mice.
2001 Mar
Temporal association between airway hyperresponsiveness and airway eosinophilia in ovalbumin-sensitized mice.
2001 Mar
Drug treatment of airway inflammation in asthma.
2001 Mar
A comparison of ovariectomy models for estrogen studies.
2001 Mar
Polycystic ovary syndrome is associated with endothelial dysfunction.
2001 Mar 13
Ascorbate restores endothelium-dependent vasodilation impaired by acute hyperglycemia in humans.
2001 Mar 27
Role of K+ channels in N-acetylprocainamide-induced relaxation of bovine tracheal smooth muscle.
2001 Mar 9
Muscarinic depression of synaptic transmission in the epileptogenic GABA withdrawal syndrome focus.
2001 May
Airway inflammation and bronchial hyperresponsiveness after Mycoplasma pneumoniae infection in a murine model.
2001 May
Occupational asthma caused by exposure to cyanoacrylate.
2001 May
Endothelial function during stimulation of renin-angiotensin system by low-sodium diet in humans.
2001 May
Patents

Sample Use Guides

Provocholine is inhaled using a standardized procedure. The challenge is performed by giving a subject ascending serial concentrations of Provocholine. At each concentration, five breaths are administered by a nebulizer that permits intermittent delivery time of 0.6 seconds by a breath-actuated timing device (dosimeter). At each of five inhalations of a serial concentration, the subject begins at functional residual capacity (FRC) and slowly and completely inhales the dose delivered. Within 5 minutes, FEV1 values are determined. The procedure ends either when there is a 20% or greater reduction in the FEV1 compared with the baseline sodium chloride solution value (i.e., a positive response) or if 188.88 total cumulative units have been administered and the FEV1 has been reduced by 14 % or less (i.e., a negative response). If there is a reduction of 15% to 19% in the FEV, compared with baseline, either the challenge may be repeated at that concentration or a higher concentration may be given as long as the dosage administered does not result in total cumulative units exceeding 188.88.
Route of Administration: Respiratory
In Vitro Use Guide
Agonist activity of methacholine was determined using assay of accumulation of [3H]inositol monophosphate. The CHO cells were labeled in 12-well plates with 1 uCi/mL myo-[3H]inositol for 24 h. Wells contained ca. 3* 10^5 cells in a volume of 1 mL. Cells were then washed once with Hank’s balanced salt media containing 20 mM HEPES buffer (pH 7.4) and were then incubated in the buffered Hank’s media containing 10 mM LiCl at room temperature for 15 min. Muscarinic agents were then added to each well. After incubation for 1 h at 37 °C, the medium was aspirated and replaced with 750 uL of cold 20 mM aqueous formic acid. After 35 min at 4 °C, the formic acid was removed and replaced with 250 uL of 60 mM NH4OH. The inositol monophosphate in the NH4OH solution was isolated by anionexchange chromatography19 and counted for tritium in Hydrofluor scintillation fluid. Cells were treated with 0.001 - 10 uM of methacholine, EC50 was determined to be 120 nM.
Name Type Language
METHACHOLINE IODIDE
Common Name English
(2-HYDROXYPROPYL)TRIMETHYLAMMONIUM IODIDE, ACETATE
Systematic Name English
2-ACETOXYPROPYLTRIMETHYLAMMONIUM IODIDE
Systematic Name English
MECHOLYL IODIDE
Common Name English
NSC-281057
Code English
(±)-ACETYL-.BETA.-METHYLCHOLINE IODIDE
Common Name English
2-(ACETYLOXY)-N,N,N-TRIMETHYLPROPAN-1-AMINIUM IODIDE
Systematic Name English
Code System Code Type Description
CAS
625-19-4
Created by admin on Sat Dec 16 06:39:18 GMT 2023 , Edited by admin on Sat Dec 16 06:39:18 GMT 2023
PRIMARY
PUBCHEM
3083639
Created by admin on Sat Dec 16 06:39:18 GMT 2023 , Edited by admin on Sat Dec 16 06:39:18 GMT 2023
PRIMARY
ECHA (EC/EINECS)
210-879-4
Created by admin on Sat Dec 16 06:39:18 GMT 2023 , Edited by admin on Sat Dec 16 06:39:18 GMT 2023
PRIMARY
FDA UNII
84CEW0PVDV
Created by admin on Sat Dec 16 06:39:18 GMT 2023 , Edited by admin on Sat Dec 16 06:39:18 GMT 2023
PRIMARY
NSC
281057
Created by admin on Sat Dec 16 06:39:18 GMT 2023 , Edited by admin on Sat Dec 16 06:39:18 GMT 2023
PRIMARY